Article Text

Download PDFPDF

103 Senile systemic amyloidosis: a common cause of heart failure in the elderly?
Free
  1. J H Pinney1,
  2. H J Lachmann2,
  3. J D Gillmore2,
  4. A Wechalekar2,
  5. S D J Gibbs3,
  6. P Sattianayagam3,
  7. S M Banypersad4,5,
  8. J Dungu6,7,
  9. N Wassef3,
  10. C A McCarthy3,
  11. P N Hawkins3,
  12. C J Whelan3
  1. 1National Amyloidosis Centre and UCL Centre for Nephrology, UCL Division of Medicine, Royal Free Hospital, London, UK
  2. 2National Amyloidosis Centre, UCL Division of Medicine, Royal Free Hospital, London, UK
  3. 3National Amyloidosis Centre, UCL Medical School, Royal Free Hospital, London, UK
  4. 4National Amyloidosis Centre, London, UK
  5. 5The Heart Hospital, UCL Medical School, London, UK
  6. 6National Amyloidosis Centre, UCL Medical School, University of London, London, UK
  7. 7St George's Hospital, University of London, London, UK

Abstract

Senile systemic amyloidosis (SSA) is a rare cause of heart failure due to the deposition of wildtype transthyretin. The clinical features and outcome are ill defined; our aim was to evaluate the natural history of the disease in the UK in a group of thoroughly characterised patients. The series included all cases of biopsy proven transthyretin (TTR) amyloidosis with wildtype TTR gene sequencing who were prospectively followed up between January 2001 and May 2010. Clinical, biochemical, ECG and echocardiographic evaluation were performed at presentation to our centre. Patient survival was estimated using Kaplan–Meier analysis. 55 patients with histologically proven SSA; 36 (65.5%) from cardiac, 14 (25.4%) from GI tract, 3 (5.5%) from bladder, 1 (1.8%) from fat and 1 (1.8%) from carpal tunnel tissue were identified. 49 (89%) were male. The median age at diagnosis and death were 74 (range 66–89) and 79 (range 69–84)  years respectively. Survival from symptom onset and diagnosis was 7.04 (range 0.54–8.41) and 4.58 (range 0.07–5.41) years respectively. In recent years more patients have been diagnosed with 2 (3.6%), 14 (25.5%) and 39 (70.9%) patients between 2001–2003, 2004–2006 and 2007–2009 respectively. The most common presentation was with breathlessness in 28 patients (51%). Twenty-four patients (43.6%) had prior carpal tunnel operations. Twelve (21.8%) patients had a history of ischaemic heart disease. Fifteen had had a coronary angiogram; 8 were reportedly normal and 7 required intervention. Arrhythmias were common, 20 patients (36.3%) had a history of atrial fibrillation and 6 (10.9) had pacemakers in situ. ECG findings were; 24 (43.6%) in AF, 6 (10.9%) first degree block, 10 (18.2%) left bundle and 6 (10.9%) right bundle branch block, 27 (49%) T wave changes, 11 (20%) <5 mm complexes in all inferior leads. Echocardiographic findings revealed the median IVSd was 1.7 (range 1.1–2.5) cm, median E/A ratio was 2.7 (range 0.79–5.4), E/E′ 15.81 (range 7.5–41.1) and ejection fraction was 45.5 (range 13–83)%. Blood results showed; the median baseline NT-proBNP was 356.1 (range 5–2611) and troponin T 0.03 (range 0.01–0.28). Twenty-five patients had a troponin T >0.03 (45%). Ten patients (18%) had a detectable paraprotein and 2 (3.6%) had bence jones proteins. SSA is present in >25% of the very elderly at post mortem but was rarely diagnosed during life. It is becoming more frequently recognised perhaps due to widespread use of cardiac MRI. Most patients are male but women can be affected. A history of carpal tunnel syndrome is common. The diagnosis is often made after the onset of breathlessness. Systolic and diastolic dysfunction can be seen on echocardiogram. A positive troponin is a common finding with a subsequent normal coronary angiogram. Incidental paraproteins are prevalent in up to 8% of this population and it is important to obtain a tissue diagnosis to rule out AL amyloidosis. With supportive management medium term outcomes are good.

  • Amyloidosis
  • heart failure
  • survival

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.